Physician profile
Sergio E Haynes
NPI 1528391901
$8,277.85
in general payments reported to CMS, 2019-2025
48 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,309 · 2023: $2,056 · 2024: $2,029 · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,686.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,430.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $862.99 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Novo Nordisk INC | $824.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $683.56 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $655.23 | 2022-2025 | |
| Lilly USA, LLC | $538.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $352.83 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $307.87 | 2021-2025 | Freestyle Libre, Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $307.77 | 2021-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.65 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $272.22 | 2021-2025 | Veozah |
| Corium, LLC | $206.45 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $171.17 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $167.47 | 2021-2025 | |
| Dexcom, INC. | $112.72 | 2021-2024 | Dexcom G6 Transmitter |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.